Clinical Trial Update: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both [Phase 3]

View source ↗

Summary

Phase 3 trial comparing CagriSema to tirzepatide for glycemic control and weight loss in adults with type 2 diabetes on_metformin and/or SGLT2 inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• CagriSema (cagrilintide/semaglutide)
• Tirzepatide (tirzepatide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: ACTIVE_NOT_RECRUITING